GRIFFON Pharmaceuticals
GRIFFON Pharmaceuticals is a biopharma company located in Montréal, Canada and Lausanne, Switzerland developing a new bifunctional peptide growth hormone releasing factor (GRF) and vasoactive intestinal peptide (VIP) analog. The company aims to develop GP119 in several indications with significant unmet needs. The company’s lead indication, LD-HIV, is commonly seen in patients with HIV with an approximate prevalence of 200,000 patients in the US.
Experienced Management Team
Extensive experience developing LD-HIV peptides as the former management of Theratechnologies, producer of tesamorelin, the only LD-HIV indicated drug currently on the market.
Significant Unmet Need
Existing therapies are inadequate due to low stability, bioavailability and long-term side-effects, and there is a significant overall market opportunity for a superior product.
Differentiated Product
First-in-class, dual peptide with clinically proven mechanisms of action to treat the symptoms of LD-HIV with additional anti-inflammatory, cardioprotective and pneumoprotective properties.
Experienced Management Team
Extensive experience developing LD-HIV peptides as the former management of Theratechnologies, producer of tesamorelin, the only LD-HIV indicated drug currently on the market.
Significant Unmet Need
Existing therapies are inadequate due to low stability, bioavailability and long-term side-effects, and there is a significant overall market opportunity for a superior product.
Differentiated Product
First-in-class, dual peptide with clinically proven mechanisms of action to treat the symptoms of LD-HIV with additional anti-inflammatory, cardioprotective and pneumoprotective properties.
GP119 for treating the symptoms of LD-HIV
GP119 is a next generation bifunctional peptide that synergistically combines the lipolytic and anabolic properties of GRF with the cardiovascular and anti-inflammatory benefits of VIP actions.
